Skip to content

S. 1095 · 119th Congress (2025–2027)

Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Show official title

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Reported

This bill’s path

This is S. 1095’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Amy Klobuchar (D-MN)
Cosponsors
6 cosponsors

6 original · 0 later

2 R · 4 D

  1. Sen. Richard Blumenthal (D-CT)· Original · Mar 24, 2025
  2. Sen. Cory A. Booker (D-NJ)· Original · Mar 24, 2025
  3. Sen. Ted Cruz (R-TX)· Original · Mar 24, 2025
  4. Sen. Richard J. Durbin (D-IL)· Original · Mar 24, 2025
  5. Sen. Chuck Grassley (R-IA)· Original · Mar 24, 2025
  6. Sen. Peter Welch (D-VT)· Original · Mar 24, 2025
Policy area
Health
Subjects
  • Administrative remedies
  • Business ethics
  • Civil actions and liability
  • Competition and antitrust
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Licensing and registrations
  • 2 more
    • Prescription drugs
    • Public participation and lobbying

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Mar 24, 2025 – Apr 10, 2025
    1. Referred to committee

      Read twice and referred to the Committee on the Judiciary.

      Sources
    2. Ordered reported

      Committee on the Judiciary. Ordered to be reported without amendment favorably.

      Sources
    3. Reported by committee

      Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

      Sources

Committees

  1. SenateJudiciaryReferred Mar 24, 2025 · Markup Apr 3, 2025 · Reported Apr 10, 2025
    1. Apr 3, 2025 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (3)
  1. Stop STALLING Act

    Short title, Display title · Reported to Senate, Introduced in Senate

  2. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

    Short title · Reported to Senate, Introduced in Senate

  3. A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

    Official title · Introduced in Senate